首页> 外文期刊>The New England journal of medicine >A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators (see comments)
【24h】

A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators (see comments)

机译:缩短齐多夫定方案预防1型人类免疫缺陷病毒母婴传播的试验(围产期HIV预防试验(泰国),研究人员)(请参阅评论)

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The optimal duration of zidovudine administration to prevent perinatal transmission of human immunodeficiency virus type 1 (HIV-1) should be determined to facilitate its use in areas where resources are limited. METHODS: We conducted a randomized, double-blind equivalence trial of zidovudine starting in the mother at 28 weeks' gestation, with 6 weeks of treatment in the infant (the long-long regimen), which is similar to protocol 076; zidovudine starting at 35 weeks' gestation, with 3 days of treatment in the infant (the short-short regimen); a long-short regimen; and a short-long regimen. The mothers received zidovudine orally during labor. The infants were fed formula and were tested for HIV DNA at 1, 45, 120, and 180 days. After the first interim analysis, the short-short regimen was stopped. RESULTS: A total of 1437 women were enrolled. At the first interim analysis, the rates of HIV transmission were 4.1 percent for the long-long regimen and 10.5 percent for the short-short regimen (P=0.004). For the entire study period, the transmission rates were 6.5 percent (95 percent confidence interval, 4.1 to 8.9 percent) for the long-long regimen, 4.7 percent (95 percent confidence interval, 2.4 to 7.0 percent) for the long-short regimen, and 8.6 percent (95 percent confidence interval, 5.6 to 11.6 percent) for the short-long regimen. The rate of in utero transmission was significantly higher with the two regimens with shorter maternal treatment (5.1 percent) than with the two with longer maternal treatment (1.6 percent). CONCLUSIONS: The short-short zidovudine regimen is inferior to the long-long regimen and leads to a higher rate of perinatal HIV transmission. The long-short, short-long, and long-long regimens had equivalent efficacy. However, the higher rate of in utero transmission with the short-long regimen suggests that longer treatment of the infant cannot substitute for longer treatment of the mother.
机译:背景:应该确定齐多夫定给药的最佳持续时间以防止围产期人类1型免疫缺陷病毒(HIV-1)的传播,以利于在资源有限的地区使用。方法:我们进行了一项齐多夫定的随机,双盲等效性试验,从母亲在妊娠28周开始,对婴儿进行了6周的治疗(长期治疗),这与076方案相似;齐多夫定从妊娠35周开始,婴儿治疗3天(短期-短期治疗);长短疗程;和短期的长期治疗。母亲在分娩时口服齐多夫定。用配方奶喂养婴儿,并在第1、45、120和180天进行HIV DNA检测。在第一次中期分析之后,停止了短期-短期治疗方案。结果:共有1437名妇女入组。在第一个中期分析中,长期-长期方案的HIV传播率为4.1%,短期-短期方案的HIV传播率为10.5%(P = 0.004)。在整个研究期间,长-长疗程的传播率为6.5%(95%置信区间为4.1至8.9%),长-短疗程的传播率为4.7%(95%置信区间为2.4至7.0%), 8.6%(95%置信区间为5.6%至11.6%)。两种产妇治疗时间较短的方案(5.1%)的宫内传播率明显高于两种母体治疗时间较长的方案(1.6%)。结论:齐多夫定短-短方案不如长-长方案,导致围生期HIV传播率更高。长短,短长和长长方案具有相同的疗效。然而,短期-长期方案的子宫内传播率更高,表明更长的婴儿治疗不能代替更长的母亲治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号